The Effect of Mercaptopurine on the DNMT I Gene in Children with B-cell Acute Lymphoblastic Leukemia

Authors
K. Rahmani 1
F. Pourrajab 2
S. Hekmatimoghaddam 3
A. Dehghani Firoozabadi 4
T. Ahmadi Afzadi 1
1 Department of Clinical Biochemistry, International Campus, Shahid Sadoughi University of Medical Science, Yazd, Iran
2 Department of Biochemistry and Molecular Biology, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
3 Cardiovascular Research Center, Shahid Sadoughi University of Medical Science, Yazd, Iran/ Department of Laboratory Sciences, School of Paramedicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
4 Cardiovascular Research Center, Shahid Sadoughi University of Medical Science, Yazd, Iran
Abstract
Objective: Considering the high incidence of acute lymphoblastic leukemia (ALL), it is necessary to research this illness and determine genetic markers associated with it. The role of DNMT I gene expression during treatment with mercaptopurine drugs in children with B-cell ALL (B-ALL) is important because its changes reflect the effectiveness or ineffectiveness of the drugs. We have investigated the effect of mercaptopurine drugs on DNMT I expression in children with B-ALL.
Methods: This analytical study assessed 8 B-ALL children who referred to Tehran Children's Medical Center and 10 healthy children referred to the Yazd Central Laboratory by convenience selection in 2016. Blood samples were obtained before and after treatment, and extraction of total RNA from each sample was performed for real-time qPCR of the target gene (DNMT I). Simultaneously, we evaluated GAPDH, a housekeeping gene. Data from gene expressions were compared by the paired t-test, using SPSS-16 software.
Results: DNMT I gene expression was significantly decreased after mercaptopurine administration in children with B-ALL (P<0.02).
Conclusion: Our findings suggest that the mercaptopurine drug may affect DNMT I gene regulation. This epigenetic effect may explain the mechanism of drug action, possibly serve as a diagnostic factor, and a means of better monitoring for patients with ALL.

Keywords

[1]  Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975; 45(3): 321-34.
[2]  Leukemia. (2014, June 13). Childhood Acute Lymphoblastic Leukemia Treatment. National Institutes of Health, National Cancer Institute (NCI). Retrieved from https://www.cancer.gov/types/leukemia/patient/child-all-treatment-pdq.
[3]  Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57(1): 43-66.
[4]  Hashemi A, Naini M, Eslami Z, Lotfi MH, Khirandish M, Rafeeyan M. Immunophenotype Children with Acute lymphoblastic leukemia, referred to Yazd hospital. Journal of Shahid Sadoughi University of Medical Sciences. 2010; 5: 56-60. (Persian)
[5]  Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, Harris CC, Lichti CF, Townsend RR, Fulton RS, Dooling DJ, Koboldt DC, Schmidt H, Zhang Q, Osborne JR, Lin L, O'Laughlin M, McMichael JF, Delehaunty KD, McGrath SD, Fulton LA, Magrini VJ, Vickery TL, Hundal J, Cook LL, Conyers JJ, Swift GW, Reed JP, Alldredge PA, Wylie T, Walker J, Kalicki J, Watson MA, Heath S, Shannon WD, Varghese N, Nagarajan R, Westervelt P, Tomasson MH, Link DC, Graubert TA, DiPersio JF, Mardis ER, Wilson RK. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363(25): 2424-33.
[6]  Gudas LJ. Retinoids induce stem cell differentiation via epigenetic changes. Semin Cell Dev Biol 2013; 24(10-12): 701-5.
[7]  Foulks JM, Parnell KM, Nix RN, Chau S, Swierczek K, Saunders M, Wright K, Hendrickson TF, Ho KK, McCullar MV, Kanner SB. Epigenetic drug discovery targeting DNA methyltransferases. J Biomol Screen 2012; 17(1): 2-17.
[8]  Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349(21): 2042-54.
[9]  Yuan B, Zhang J, Wang H, Xiong L, Cai Q, Wang T, Jacobsen S, Pradhan S, Wang Y. 6-Thioguanine reactivates epigenetically silenced genes in acute lymphoblastic leukemia cells by facilitating proteasome-mediated degradation of DNMT1. Cancer Res 2011; 71(5): 1904-11.
[10] Tang Y, Luo Y, Jiang Z, Ma Y, Lin CJ, Kim C, Carter MG, Amano T, Park J, Kish S, Tian XC. Jak/Stat3 signaling promotes somatic cell reprogramming by epigenetic regulation. Stem Cells 2012; 30(12): 2645-56.
[11] Wolfraim LA, Fernandez TM, Mamura M, Fuller WL, Kumar R, Cole DE, Byfield S, Felici A, Flanders KC, Walz TM, Roberts AB, Aplan PD, Balis FM, Letterio JJ. Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl J Med 2004; 351(6): 552-9.
[12] McFarlin DE, McFarland HF. Multiple sclerosis (first of two parts). N Engl J Med 1982; 307(19): 1183-8.
[13] Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005; 23: 683-747.
[14] Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001; 10(7): 687-92.
[15] Holliday R. DNA methylation and epigenetic inheritance. Philosophical transactions of the Royal Society of London Series B, Biological sciences. 1990; 326(1235): 329-38.
[16] Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y, Sasaki H. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001; 97(5): 1172-9.
[17]  Liu ZJ, Zhang XB, Zhang Y, Yang X. Progesterone receptor gene inactivation and CpG island hypermethylation in human leukemia cancer cells. FEBS Lett 2004; 567(2-3): 327-32.
[18]  Lopez A, Mounier M, Bouvier AM, Carrat F, Maynadie M, Beaugerie L, Peyrin-Biroulet L; CESAME Study Group. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. Clin Gastroenterol Hepatol 2014; 12(8): 1324-9.
[19]  Tanaka Y, Kato M, Hasegawa D, Urayama KY, Nakadate H, Kondoh K, Nakamura K, Koh K, Komiyama T, Manabe A. Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia. Br J Haematol 2015; 171(1): 109-15.
[20]  Yang JJ, Landier W, Yang W, Liu C, Hageman L, Cheng C, Pei D, Chen Y, Crews KR, Kornegay N, Wong FL, Evans WE, Pui CH, Bhatia S, Relling MV. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol 2015; 33(11): 1235-42.
Pathobiology Reserach
Volume 20, Issue 1
June 2017
Pages 17-28